Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?

Z. Balogh, I. Seres, M. Harangi, P. Kovács, G. Kakuk, G. Paragh

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: The constellation of elevated triglycerides and decreased high-density lipoprotein is recognised as a risk factor for CAD and constitutes the major dyslipidemia in type 2 diabetes. The high-density lipoprotein associated paraoxonase activity can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. To determine the effect of gemfibrozil on the dyslipidemia and serum paraoxonase activity in patients with type 2 diabetes. Material and methods: Fifty-six type 2 diabetic patients with associated hypertriglyceridemia were involved. They were investigated for the effect of twice daily 600 mg of gemfibrozil on serum cholesterol, triglycerides, apolipoproteins, fibrinogen level, body mass index and glycated hemoglobin. Serum paraoxonase activity was measured spectrophotometrically. Results: After three months, it was observed that under the effect of gemfibrozil, serum triglyceride level was significantly decreased (from median: 3.46 mmol/l quartiles: q1 = 2.92 q3 = 5.28 to median 2.20 mmol/l quartiles: q1 = 1.79 q3 = 3.65; p <0.001) while protective high-density lipoprotein (from 1.02 ± 0.22 mmol/l to 1.13 ± 0.28 mmol/l; p = 0.05) and apolipoprotein A1 (from 1.56 ± 0.33 g/l to 1.72 ± 0.29; p <0.01) levels were significantly increased. Serum paraoxonase activity was found to be significantly increased (from median: 100.2 U/l quartiles: q1=60.1 q3 = 152.7 to median 118.7 U/l quartiles: q1 = 80.1 q3 = 171.0; p <0.001) after gemfibrozil treatment. The total cholesterol, low-density lipoprotein, apolipoprotein B, lipoprotein (a), glycated hemoglobin and fibrinogen levels were not significantly changed during the three-month treatment period. The standardized paraoxonase activity for HDL and apo A1 were not significantly changed. Paraoxonase activity did not correlate with the concentration of glycohemoglobin and the duration of diabetes. Conclusion: Twice daily administration of 600 mg of gemfibrozil is effective in type 2 diabetic patients with associated hypertriglyceridemia. It favorably lowers lipid levels, and improves antioxidant status by increasing serum paraoxonase activity.

Original languageEnglish
Pages (from-to)604-610
Number of pages7
JournalDiabetes and Metabolism
Volume27
Issue number5 I
Publication statusPublished - 2001

Fingerprint

Gemfibrozil
Aryldialkylphosphatase
Fibric Acids
HDL Lipoproteins
Serum
Triglycerides
Hypertriglyceridemia
Apolipoprotein A-I
Glycosylated Hemoglobin A
Dyslipidemias
Fibrinogen
Type 2 Diabetes Mellitus
Lipoprotein(a)
Apolipoproteins
Apolipoproteins B
LDL Lipoproteins
LDL Cholesterol
Body Mass Index
Antioxidants
Cholesterol

Keywords

  • Diabetes mellitus
  • Gemfibrozil
  • Paraoxonase
  • Triglyceride

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{832569168ba049e49f00c27d9236eb2f,
title = "Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?",
abstract = "Objective: The constellation of elevated triglycerides and decreased high-density lipoprotein is recognised as a risk factor for CAD and constitutes the major dyslipidemia in type 2 diabetes. The high-density lipoprotein associated paraoxonase activity can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. To determine the effect of gemfibrozil on the dyslipidemia and serum paraoxonase activity in patients with type 2 diabetes. Material and methods: Fifty-six type 2 diabetic patients with associated hypertriglyceridemia were involved. They were investigated for the effect of twice daily 600 mg of gemfibrozil on serum cholesterol, triglycerides, apolipoproteins, fibrinogen level, body mass index and glycated hemoglobin. Serum paraoxonase activity was measured spectrophotometrically. Results: After three months, it was observed that under the effect of gemfibrozil, serum triglyceride level was significantly decreased (from median: 3.46 mmol/l quartiles: q1 = 2.92 q3 = 5.28 to median 2.20 mmol/l quartiles: q1 = 1.79 q3 = 3.65; p <0.001) while protective high-density lipoprotein (from 1.02 ± 0.22 mmol/l to 1.13 ± 0.28 mmol/l; p = 0.05) and apolipoprotein A1 (from 1.56 ± 0.33 g/l to 1.72 ± 0.29; p <0.01) levels were significantly increased. Serum paraoxonase activity was found to be significantly increased (from median: 100.2 U/l quartiles: q1=60.1 q3 = 152.7 to median 118.7 U/l quartiles: q1 = 80.1 q3 = 171.0; p <0.001) after gemfibrozil treatment. The total cholesterol, low-density lipoprotein, apolipoprotein B, lipoprotein (a), glycated hemoglobin and fibrinogen levels were not significantly changed during the three-month treatment period. The standardized paraoxonase activity for HDL and apo A1 were not significantly changed. Paraoxonase activity did not correlate with the concentration of glycohemoglobin and the duration of diabetes. Conclusion: Twice daily administration of 600 mg of gemfibrozil is effective in type 2 diabetic patients with associated hypertriglyceridemia. It favorably lowers lipid levels, and improves antioxidant status by increasing serum paraoxonase activity.",
keywords = "Diabetes mellitus, Gemfibrozil, Paraoxonase, Triglyceride",
author = "Z. Balogh and I. Seres and M. Harangi and P. Kov{\'a}cs and G. Kakuk and G. Paragh",
year = "2001",
language = "English",
volume = "27",
pages = "604--610",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "5 I",

}

TY - JOUR

T1 - Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?

AU - Balogh, Z.

AU - Seres, I.

AU - Harangi, M.

AU - Kovács, P.

AU - Kakuk, G.

AU - Paragh, G.

PY - 2001

Y1 - 2001

N2 - Objective: The constellation of elevated triglycerides and decreased high-density lipoprotein is recognised as a risk factor for CAD and constitutes the major dyslipidemia in type 2 diabetes. The high-density lipoprotein associated paraoxonase activity can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. To determine the effect of gemfibrozil on the dyslipidemia and serum paraoxonase activity in patients with type 2 diabetes. Material and methods: Fifty-six type 2 diabetic patients with associated hypertriglyceridemia were involved. They were investigated for the effect of twice daily 600 mg of gemfibrozil on serum cholesterol, triglycerides, apolipoproteins, fibrinogen level, body mass index and glycated hemoglobin. Serum paraoxonase activity was measured spectrophotometrically. Results: After three months, it was observed that under the effect of gemfibrozil, serum triglyceride level was significantly decreased (from median: 3.46 mmol/l quartiles: q1 = 2.92 q3 = 5.28 to median 2.20 mmol/l quartiles: q1 = 1.79 q3 = 3.65; p <0.001) while protective high-density lipoprotein (from 1.02 ± 0.22 mmol/l to 1.13 ± 0.28 mmol/l; p = 0.05) and apolipoprotein A1 (from 1.56 ± 0.33 g/l to 1.72 ± 0.29; p <0.01) levels were significantly increased. Serum paraoxonase activity was found to be significantly increased (from median: 100.2 U/l quartiles: q1=60.1 q3 = 152.7 to median 118.7 U/l quartiles: q1 = 80.1 q3 = 171.0; p <0.001) after gemfibrozil treatment. The total cholesterol, low-density lipoprotein, apolipoprotein B, lipoprotein (a), glycated hemoglobin and fibrinogen levels were not significantly changed during the three-month treatment period. The standardized paraoxonase activity for HDL and apo A1 were not significantly changed. Paraoxonase activity did not correlate with the concentration of glycohemoglobin and the duration of diabetes. Conclusion: Twice daily administration of 600 mg of gemfibrozil is effective in type 2 diabetic patients with associated hypertriglyceridemia. It favorably lowers lipid levels, and improves antioxidant status by increasing serum paraoxonase activity.

AB - Objective: The constellation of elevated triglycerides and decreased high-density lipoprotein is recognised as a risk factor for CAD and constitutes the major dyslipidemia in type 2 diabetes. The high-density lipoprotein associated paraoxonase activity can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. To determine the effect of gemfibrozil on the dyslipidemia and serum paraoxonase activity in patients with type 2 diabetes. Material and methods: Fifty-six type 2 diabetic patients with associated hypertriglyceridemia were involved. They were investigated for the effect of twice daily 600 mg of gemfibrozil on serum cholesterol, triglycerides, apolipoproteins, fibrinogen level, body mass index and glycated hemoglobin. Serum paraoxonase activity was measured spectrophotometrically. Results: After three months, it was observed that under the effect of gemfibrozil, serum triglyceride level was significantly decreased (from median: 3.46 mmol/l quartiles: q1 = 2.92 q3 = 5.28 to median 2.20 mmol/l quartiles: q1 = 1.79 q3 = 3.65; p <0.001) while protective high-density lipoprotein (from 1.02 ± 0.22 mmol/l to 1.13 ± 0.28 mmol/l; p = 0.05) and apolipoprotein A1 (from 1.56 ± 0.33 g/l to 1.72 ± 0.29; p <0.01) levels were significantly increased. Serum paraoxonase activity was found to be significantly increased (from median: 100.2 U/l quartiles: q1=60.1 q3 = 152.7 to median 118.7 U/l quartiles: q1 = 80.1 q3 = 171.0; p <0.001) after gemfibrozil treatment. The total cholesterol, low-density lipoprotein, apolipoprotein B, lipoprotein (a), glycated hemoglobin and fibrinogen levels were not significantly changed during the three-month treatment period. The standardized paraoxonase activity for HDL and apo A1 were not significantly changed. Paraoxonase activity did not correlate with the concentration of glycohemoglobin and the duration of diabetes. Conclusion: Twice daily administration of 600 mg of gemfibrozil is effective in type 2 diabetic patients with associated hypertriglyceridemia. It favorably lowers lipid levels, and improves antioxidant status by increasing serum paraoxonase activity.

KW - Diabetes mellitus

KW - Gemfibrozil

KW - Paraoxonase

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=0035155790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035155790&partnerID=8YFLogxK

M3 - Article

C2 - 11694861

AN - SCOPUS:0035155790

VL - 27

SP - 604

EP - 610

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 5 I

ER -